InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing
Vancouver, BC – September 22, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"
, today announced the filing of a patent application as part of a growing portfolio of intellectual property related to the IntegraSyn™ manufacturing approach for producing low-cost, pharmaceutical-grade cannabinoids.
The patent, entitled “Compositions and Methods for Aromatic Prenylation”, describes a novel enzyme used to overcome one of the more significant challenges of producing cannabinoids at a high yield. Cannabinoids, including their rare forms, are complex molecules that require specific modification and assembly, through multiple steps, to generate the correct, final chemical structure. To date, attempts by industry and researchers to produce pharmaceutical-grade cannabinoids by reproducing this precise biological process outside of the natural plant, at low cost and large scale, have been challenging using available biosynthesis or chemical synthesis methodologies. By engineering variants of the bacterium E. coli, our scientists, working with Almac Group, have developed a proprietary enzyme that can efficiently assemble the primary gateway cannabinoid cannabigerolic acid (“CBGA”). CBGA can be subsequently modified through several pathways to manufacture a number of naturally occurring cannabinoids. In plants, synthesis of CBGA is the most dominant pathway resulting in high quantities of the down-stream cannabinoids such as THC and CBD. This proprietary enzyme fits directly into, and plays an integral part of, the Company’s IntegraSyn™ manufacturing approach.
About InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol ("CBN" in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.
About IntegraSyn™: IntegraSyn™ is InMed’s integrated cannabinoid manufacturing system designed to efficiently and economically produce pharmaceutical-grade, bio-identical cannabinoids. The scalable and flexible IntegraSyn™ manufacturing system integrates multiple commercially proven methods to efficiently produce cannabinoids utilizing cost-effective processes.
Investor Contact:
InMed Pharmaceuticals Inc.
Brendan Payne, Director – Investor Relations
T: +1.604.669.7207
E: info@inmedpharma.com
Edison Advisors for InMed Pharmaceuticals
Ethan Walfish / Laine Yonker
T: +1.646.760.0321 / +1 646 653 7035
E: ewalfish@edisongroup.com
lyonker@edisongroup.com
Source: InMed Pharmaceuticals (info@inmedpharma.com)
Vancouver, BC – September 22, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"
, today announced the filing of a patent application as part of a growing portfolio of intellectual property related to the IntegraSyn™ manufacturing approach for producing low-cost, pharmaceutical-grade cannabinoids. The patent, entitled “Compositions and Methods for Aromatic Prenylation”, describes a novel enzyme used to overcome one of the more significant challenges of producing cannabinoids at a high yield. Cannabinoids, including their rare forms, are complex molecules that require specific modification and assembly, through multiple steps, to generate the correct, final chemical structure. To date, attempts by industry and researchers to produce pharmaceutical-grade cannabinoids by reproducing this precise biological process outside of the natural plant, at low cost and large scale, have been challenging using available biosynthesis or chemical synthesis methodologies. By engineering variants of the bacterium E. coli, our scientists, working with Almac Group, have developed a proprietary enzyme that can efficiently assemble the primary gateway cannabinoid cannabigerolic acid (“CBGA”). CBGA can be subsequently modified through several pathways to manufacture a number of naturally occurring cannabinoids. In plants, synthesis of CBGA is the most dominant pathway resulting in high quantities of the down-stream cannabinoids such as THC and CBD. This proprietary enzyme fits directly into, and plays an integral part of, the Company’s IntegraSyn™ manufacturing approach.
About InMed: InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol ("CBN"
in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com. About IntegraSyn™: IntegraSyn™ is InMed’s integrated cannabinoid manufacturing system designed to efficiently and economically produce pharmaceutical-grade, bio-identical cannabinoids. The scalable and flexible IntegraSyn™ manufacturing system integrates multiple commercially proven methods to efficiently produce cannabinoids utilizing cost-effective processes.
Investor Contact:
InMed Pharmaceuticals Inc.
Brendan Payne, Director – Investor Relations
T: +1.604.669.7207
E: info@inmedpharma.com
Edison Advisors for InMed Pharmaceuticals
Ethan Walfish / Laine Yonker
T: +1.646.760.0321 / +1 646 653 7035
E: ewalfish@edisongroup.com
lyonker@edisongroup.com
Source: InMed Pharmaceuticals (info@inmedpharma.com)
1
